The European Commission has given its approval to the oral factor Xa inhibitor rivaroxaban (Xarelto, Bayer Pharma/Janssen Pharmaceuticals) for secondary prevention in adult patients who have had biomarker-confirmed acute coronary syndrome (ACS), The indication is for 2.5-mg twice daily in combination with standard antiplatelet therapy.
Reference: ATLAS ACS 2 TIMI 51 trial
Nessun commento:
Posta un commento